National Science Foundation has issued a special Small Business Innovation Research (SBIR) Phase IB award to Bacterial Robotics for the development on non-surgical methods for treating Cholesteatoma, benign tumors of the temporal bone, ear, and skull base that can cause deafness, dizziness, facial palsy, brain abscess, and meningitis.
According to Dr. Ravi Samy, MD, FACS, Bacterial Robotics' Chief Medical Officer, as well as the Director of the Neurotology Fellowship at the University of Cincinnati, College of Medicine, Director of the Adult Cochlear Implant Program, and Associate Professor of the Department of Otolaryngology."Skull-base tumors destroy hearing and can lead to death if untreated. We are also concerned about the high rates of recurrence that require repeatedly invasive, risky, and expensive surgeries.Residual cells may lead to recurrence rates as high as 10% in areas where the most sophisticated care is available. Recurrence rates above 70% in less economically developed regions of the world are not uncommon. Our effort is meant to be life-changing and life-saving."
The BactoBot (aka AuriBot(TM), is being developed to augment current skull-based surgical practices by "killing microscopic cholesteatoma cells remaining after surgery in order to reduce the high recurrence rates." Bacterial Robotics intends to provide an unannounced go-to-market expert firm with the resulting BactoBot oncolytic product that can be delivered to surgeons. who perform approximately 150,000 such operations per year at a cost of around $40,000 each,
For more information readers can check out the on Bacterial Robotics website at http://BacterialRobotics.com.